Increased risk of developing cutaneous malignant melanoma is associated with variation in pigmentation genes and VDR, and may involve epistatic effects

Melanoma Research

Volumn 24, Issue 4, 2014, Pages 388-396

  Kosiniak Kamysz, Agnieszka ^a   Marczakiewicz Lustig, Anna ^a   Marcińska, Magdalena ^c   Skowron, Małgorzata ^a   Wojas Pelc, Anna ^a   Pośpiech, Ewelina ^b   Branicki, Wojciech ^b,c  

^a JAGIELLONIAN UNIVERSITY MEDICAL COLLEGE   (Poland)

^b JAGIELLONIAN UNIVERSITY   (Poland)

^c INSTITUTE OF FORENSIC RESEARCH   (Poland)

Author keywords

association; cutaneous malignant melanoma; gene gene interactions; pigmentation genes; VDR

Indexed keywords

VITAMIN D RECEPTOR; CALCITRIOL RECEPTOR; VDR PROTEIN, HUMAN;

ADULT; ARTICLE; CONTROLLED STUDY; CUTANEOUS MALIGNANT MELANOMA; CUTANEOUS MELANOMA; DNA POLYMORPHISM; EPISTASIS; EYE COLOR; FEMALE; GENE INTERACTION; GENE LINKAGE DISEQUILIBRIUM; GENE MUTATION; GENETIC ASSOCIATION; GENETIC RISK; GENETIC VARIABILITY; HAIR COLOR; HAPLOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; PHENOTYPE; POLAND; PRIORITY JOURNAL; SKIN PIGMENTATION; CASE CONTROL STUDY; GENETIC PREDISPOSITION; GENETICS; GENOTYPE; MELANOMA; MIDDLE AGED; PATHOLOGY; QUESTIONNAIRE; RISK FACTOR; SINGLE NUCLEOTIDE POLYMORPHISM; SKIN TUMOR;

CASE-CONTROL STUDIES; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; MALE; MELANOMA; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; QUESTIONNAIRES; RECEPTORS, CALCITRIOL; RISK FACTORS; SKIN NEOPLASMS; SKIN PIGMENTATION;

EID: 84904066512     PISSN: 09608931     EISSN: 14735636     Source Type: Journal    
DOI: 10.1097/CMR.0000000000000095     Document Type: Article

References (92)

1. Olsen CM, Carroll HJ, Whiteman DC. Estimating the attributable fraction for melanoma: a meta-analysis of pigmentary characteristics and freckling. Int J Cancer 2010; 127:2430-2445.
2. Erdmann F, Lortet-Tieulent J, Schüz J, Zeeb H, Greinert R, Breitbart EW, Bray F. International trends in the incidence of malignant melanoma 1953-2008-are recent generations at higher or lower risk? Int J Cancer 2013; 132:385-400.
3. Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J, Rosso S, Coebergh JW, Comber H, et al. Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. Eur J Cancer 2013; 49:1374-1403.
4. Rebecca VW, Sondak VK, Smalley KS. A brief history of melanoma: from mummies to mutations. Melanoma Res 2012; 22:114-122.
5. Kennedy C, ter Huurne J, Berkhout M, Gruis N, Bastiaens M, Bergman W, et al. Melanocortin 1 receptor (MC1R) gene variants are associated with an increased risk for cutaneous melanoma which is largely independent of skin type and hair color. J Invest Dermatol 2001; 117:294-300.
6. Stratigos AJ, Dimisianos G, Nikolaou V, Poulou M, Sypsa V, Stefanaki I, et al. Melanocortin receptor-1 gene polymorphisms and the risk of cutaneous melanoma in a low-risk southern European population. J Invest Dermatol 2006; 126:1842-1849.
7. Brudnik U, Branicki W, Wojas-Pelc A, Kanas P. The contribution of melanocortin 1 receptor gene polymorphisms and the agouti signalling protein gene 8818A G polymorphism to cutaneous melanoma and basal cell carcinoma in a Polish population. Exp Dermatol 2009; 18:167-174.
8. Valverde P, Healy E, Sikkink S, Haldane F, Thody AJ, Carothers A, et al. The Asp84Glu variant of the melanocortin 1 receptor (MC1R) is associated with melanoma. Hum Mol Genet 1996; 5:1663-1666.
9. Palmer JS, Duffy DL, Box NF, Aitken JF, O'Gorman LE, Green AC, et al. MC1R polymorphisms and risk of melanoma: is the association explained solely by pigmentation phenotype? Am J Hum Genet 2000; 66:176-186.
10. Box NF, Duffy DL, Chen W, Stark M, Martin NG, Sturm RA, Hayward NK. MC1R genotype modifies risk of melanoma in families segregating CDKN2A mutations. Am J Hum Genet 2001; 69:765-773.
11. Dwyer T, Stankovich JM, Blizzard L, FitzGerald LM, Dickinson JL, Reilly A, et al. Does the addition of information on genotype improve prediction of the risk of melanoma and nonmelanoma skin cancer beyond that obtained from skin phenotype? Am J Epidemiol 2004; 159:826-833.
12. Fernandez LP, Milne RL, Pita G, Avilés JA, Lázaro P, Benítez J, Ribas G. SLC45A2: a novel malignant melanoma-associated gene. Hum Mutat 2008; 29:1161-1167.
13. Guedj M, Bourillon A, Combadières C, Rodero M, Dieudé P, Descamps V, et al. Melan Cohort Investigators. Variants of the MATP/SLC45A2 gene are protective for melanoma in the French population. Hum Mutat 2008; 29:1154-1160.
14. Gudbjartsson DF, Sulem P, Stacey SN, Goldstein AM, Rafnar T, Sigurgeirsson B, et al. ASIP and TYR pigmentation variants associate with cutaneous melanoma and basal cell carcinoma. Nat Genet 2008; 40:886-891.
15. Amos CI, Wang LE, Lee JE, Gershenwald JE, Chen WV, Fang S, et al. Genome-wide association study identifies novel loci predisposing to cutaneous melanoma. Hum Mol Genet 2011; 20:5012-5023.
16. Jannot AS, Meziani R, Bertrand G, Gérard B, Descamps V, Archimbaud A, et al. Allele variations in the OCA2 gene (pink-eyed-dilution locus) are associated with genetic susceptibility to melanoma. Eur J Hum Genet 2005; 13:913-920.
17. Duffy DL, Iles MM, Glass D, Zhu G, Barrett JH, Höiom V, et al. IRF4 variants have age-specific effects on nevus count and predispose to melanoma. Am J Hum Genet 2010; 87:6-16.
18. Duffy DL, Zhao ZZ, Sturm RA, Hayward NK, Martin NG, Montgomery GW. Multiple pigmentation gene polymorphisms account for a substantial proportion of risk of cutaneous malignant melanoma. J Invest Dermatol 2010; 130:520-528.
19. Stefanaki I, Panagiotou OA, Kodela E, Gogas H, Kypreou KP, Chatzinasiou F, et al. Replication and predictive value of SNPs associated with melanoma and pigmentation traits in a Southern European case-control study. PLoS One 2013; 8:e55712.
20. Kvaskoff M, Whiteman DC, Zhao ZZ, Montgomery GW, Martin NG, Hayward NK, Duffy DL. Polymorphisms in nevus-associated genes MTAP, PLA2G6, and IRF4 and the risk of invasive cutaneous melanoma. Twin Res Hum Genet 2011; 14:422-432.
21. Pena-Chilet M, Blanquer-Maceiras M, Ibarrola-Villava M, Martinez-Cadenas C, Martin-Gonzalez M, Gomez-Fernandez C, et al. Genetic variants in PARP1 (rs3219090) and IRF4 (rs12203592) genes associated with melanoma susceptibility in a Spanish population. BMC Cancer 2013; 13:160.
22. Liu F, van Duijn K, Vingerling JR, Hofman A, Uitterlinden AG, Janssens AC, Kayser M. Eye color and the prediction of complex phenotypes from genotypes. Curr Biol 2009; 19:R192-R193.
23. Ruiz Y, Phillips C, Gomez-Tato A, Alvarez-Dios J, Casares de Cal M, Cruz R, et al. Further development of forensic eye color predictive tests. Forensic Sci Int Genet 2013; 7:28-40.
24. Carlberg C, Seuter S, Heikkinen S. The first genome-wide view of vitamin D receptor locations and their mechanistic implications. Anticancer Res 2012; 32:271-282.
25. Hutchinson PE, Osborne JE, Lear JT, Smith AG, Bowers PW, Morris PN, et al. Vitamin D receptor polymorphisms are associated with altered prognosis in patients with malignant melanoma. Clin Cancer Res 2000; 6:498-504.
26. Halsall JA, Osborne JE, Potter L, Pringle JH, Hutchinson PE. A novel polymorphism in the 1A promoter region of the vitamin D receptor is associated with altered susceptibility and prognosis in malignant melanoma. Br J Cancer 2004; 91:765-770.
27. Li C, Liu Z, Zhang Z, Strom SS, Gershenwald JE, Prieto VG, et al. Genetic variants of the vitamin D receptor gene alter risk of cutaneous melanoma. J Invest Dermatol 2007; 127:276-280.
28. Denzer N, Vogt T, Reichrath J. Vitamin D receptor (VDR) polymorphisms and skin cancer: a systematic review. Dermatoendocrinol 2011; 3:205-210.
29. Orlow I, Roy P, Reiner AS, Yoo S, Patel H, Paine S, et al. GEM Study Group. Vitamin D receptor polymorphisms in patients with cutaneous melanoma. Int J Cancer 2012; 130:405-418.
30. Fitzpatrick TB. Ultraviolet-induced pigmentary changes: benefits and hazards. Curr Probl Dermatol 1986; 15:25-38.
31. Popiech E, Draus-Barini J, Kupiec T, Wojas-Pelc A, Branicki W. Gene-gene interactions contribute to eye colour variation in humans. J Hum Genet 2011; 56:447-455.
32. Popiech E, Wojas-Pelc A, Walsh S, Liu F, Maeda H, Ishikawa T, et al. The common occurrence of epistasis in the determination of human pigmentation and its impact on DNA-based pigmentation phenotype prediction. Forensic Sci Int Genet 2014; 11C:64-72.
33. Hallsal JA, Osborne JE, Epstein MP, Pringle JH, Peter E, Hutchinson PE. The unfavorable effect of the A allele of the vitamin D receptor promoter polymorphism A-1012G has different mechanisms related to susceptibility and outcome of malignant melanoma. Dermatoendocrinol 2009; 1:54-57.
34. Nejentsev S, Godfrey L, Snook H, Rance H, Nutland S, Walker NM, et al. Comparative high-resolution analysis of linkage disequilibrium and tag single nucleotide polymorphisms between populations in the vitamin D receptor gene. Hum Mol Genet 2004; 13:1633-1639.
35. Dempfle A, Wudy SA, Saar K, Hagemann S, Friedel S, Scherag A, et al. Evidence for involvement of the vitamin D receptor gene in idiopathic short stature via a genome-wide linkage study and subsequent association studies. Hum Mol Genet 2006; 15:2772-2783.
36. Branicki W, Brudnik U, Wojas-Pelc A. Interactions between HERC2, OCA2 and MC1R may influence human pigmentation phenotype. Ann Hum Genet 2009; 73:160-170.
37. Ranadive NS, Shirwadkar S, Persad S, Menon IA. Effects of melanininduced free radicals on the isolated rat peritoneal mast cells. J Invest Dermatol 1986; 86:303-307.
38. Mitra D, Luo X, Morgan A, Wang J, Hoang MP, Lo J, et al. An ultravioletradiation-independent pathway to melanoma carcinogenesis in the red hair/fair skin background. Nature 2012; 491:449-453.
39. Van der Velden PA, Sandkuijl LA, Bergman W, Pavel S, van Mourik L, Frants RR, Gruis NA. Melanocortin-1 receptor variant R151C modifies melanoma risk in Dutch families with melanoma. Am J Hum Genet 2001; 69:774-779.
40. Matichard E, Verpillat P, Meziani R, Gérard B, Descamps V, Legroux E, et al. Melanocortin 1 receptor (MC1R) gene variants may increase the risk of melanoma in France independently of clinical risk factors and UV exposure. J Med Genet 2004; 41:e13.
41. Landi MT, Kanetsky PA, Tsang S, Gold B, Munroe D, Rebbeck T, et al. MC1R, ASIP, and DNA repair in sporadic and familial melanoma in a Mediterranean population. J Natl Cancer Inst 2005; 97:998-1007.
42. Dbniak T, Scott R, Masojc B, Serrano-Fernández P, Huzarski T, Byrski T, et al. MC1R common variants, CDKN2A and their association with melanoma and breast cancer risk. Int J Cancer 2006; 119:2597-2602.
43. Han J, Kraft P, Colditz GA, Wong J, Hunter DJ. Melanocortin 1 receptor variants and skin cancer risk. Int J Cancer 2006; 119:1976-1984.
44. Fargnoli MC, Spica T, Sera F, Pellacani G, Chiarugi A, Seidenari S, et al. Re: MC1R, ASIP, and DNA repair in sporadic and familial melanoma in a Mediterranean population. J Natl Cancer Inst 2006; 98:144-145.
45. Kanetsky PA, Rebbeck TR, Hummer AJ, Panossian S, Armstrong BK, Kricker A, et al. Population-based study of natural variation in the melanocortin-1 receptor gene and melanoma. Cancer Res 2006; 66:9330-9337.
46. Mössner R, Anders N, König IR, Krüger U, Schmidt D, Berking C, et al. Variations of the melanocortin-1 receptor and the glutathione-S transferase T1 and M1 genes in cutaneous malignant melanoma. Arch Dermatol Res 2007; 298:371-379.
47. Fernandez L, Milne R, Bravo J, Lopez J, Avilés J, Longo M, et al. MC1R: three novel variants identified in a malignant melanoma association study in the Spanish population. Carcinogenesis 2007; 28:1659-1664.
48. Galore-Haskel G, Azizi E, Mohamdi H, Scope A, Chaudru V, Laitman Y, et al. MC1R variant alleles and malignant melanoma risk in Israel. Eur J Cancer 2009; 45:2015-2022.
49. Council ML, Gardner JM, Helms C, Liu Y, Cornelius LA, Bowcock AM. Contribution of genetic factors for melanoma susceptibility in sporadic US melanoma patients. Exp Dermatol 2009; 18:485-487.
50. Scherer D, Nagore E, Bermejo JL, Figl A, Botella-Estrada R, Thirumaran RK, et al. Melanocortin receptor 1 variants and melanoma risk: a study of 2 European populations. Int J Cancer 2009; 125:1868-1875.
51. Kanetsky PA, Panossian S, Elder DE, Guerry D, Ming ME, Schuchter L, Rebbeck TR. Does MC1R genotype convey information about melanoma risk beyond risk phenotypes? Cancer 2010; 116:2416-2428.
52. Cust AE, Goumas C, Holland EA, Agha-Hamilton C, Aitken JF, Armstrong BK, et al. MC1R genotypes and risk of melanoma before age 40 years: a population-based case-control-family study. Int J Cancer 2012; 131:E269-E281.
53. Córdoba-Lanús E, Hernández-Jiménez JG, Medina-Coello C, Espinoza-Jiménez A, González A, Rodríguez-Pérez MD, et al. MC1R gene variants and sporadic malignant melanoma susceptibility in the Canary Islands population. Arch Dermatol Res 2014; 306:51-58.
54. Valverde P, Healy E, Jackson I, Rees JL, Thody AJ. Variants of the melanocyte-stimulating hormone receptor gene are associated with red hair and fair skin in humans. Nat Genet 1995; 11:328-330.
55. Slominski A, Tobin DJ, Shibahara S, Wortsman J. Melanin pigmentation in mammalian skin and its hormonal regulation. Physiol Rev 2004; 84:1155-1228.
56. Smith R, Healy E, Siddiqui S, Flanagan N, Steijlen PM, Rosdahl I, et al. Melanocortin 1 receptor variants in an Irish population. J Invest Dermatol 1998; 111:119-122.
57. Bastiaens MT, ter Huurne JA, Kielich C, Gruis NA, Westendorp RG, Vermeer BJ, Bavinck JN. Leiden Skin Cancer Study Team. Melanocortin-1 receptor gene variants determine the risk of nonmelanoma skin cancer independently of fair skin and red hair. Am J Hum Genet 2001; 68:884-894.
58. Scherer D, Bermejo JL, Rudnai P, Gurzau E, Koppova K, Hemminki K, Kumar R. MC1R variants associated susceptibility to basal cell carcinoma of skin: interaction with host factors and XRCC3 polymorphism. Int J Cancer 2008; 122:1787-1793.
59. Kosiniak-Kamysz A, Popiech E, Wojas-Pelc A, Marciska M, Branicki W. Potential association of single nucleotide polymorphisms in pigmentation genes with the development of basal cell carcinoma. J Dermatol 2012; 39:693-698.
60. Bishop DT, Demenais F, Iles MM, Harland M, Taylor JC, Corda E, et al. Genome-wide association study identifies three loci associated with melanoma risk. Nat Genet 2009; 41:920-925.
61. Ibarrola-Villava M, Fernandez LP, Alonso S, Boyano MD, Pena-Chilet M, Pita G, et al. A customized pigmentation SNP array identifies a novel SNP associated with melanoma predisposition in theSLC45A2 gene. PloS One 2011; 6:e19271.
62. Mártinez-García M, Montoliu L. Albinism in Europe. J Dermatol 2013; 40:319-324.
63. Graf J, Hodgson R, van Daal A. Single nucleotide polymorphisms in the MATP gene are associated with normal human pigmentation variation. Hum Mutat 2005; 25:278-284.
64. Branicki W, Brudnik U, Draus-Barini J, Kupiec T, Wojas-Pelc A. Association of the SLC45A2 gene with physiological human hair colour variation. J Hum Genet 2008; 53:966-971.
65. Branicki W, Liu F, van Duijn K, Draus-Barini J, Popiech E, Walsh S, et al. Model-based prediction of human hair color using DNA variants. Hum Genet 2011; 129:443-454.
66. Nan H, Kraft P, Hunter DJ, Han J. Genetic variants in pigmentation genes, pigmentary phenotypes, and risk of skin cancer in Caucasians. Int J Cancer 2009; 125:909-917.
67. Stacey SN, Sulem P, Masson G, Gudjonsson SA, Thorleifsson G, Jakobsdottir M, et al. New common variants affecting susceptibility to basal cell carcinoma. Nat Genet 2009; 41:909-914.
68. Walsh S, Liu F, Wollstein A, Kovatsi L, Ralf A, Kosiniak-Kamysz A, et al. The HIrisPlex system for simultaneous prediction of hair and eye colour from DNA. Forensic Sci Int Genet 2013; 7:98-115.
69. Broyna AA, Jówicki W, Carlson JA, Slominski AT. Melanogenesis affects overall and disease-free survival in patients with stage III and IV melanoma. Hum Pathol 2013; 44:2071-2074.
70. Brozyna AA, VanMiddlesworth L, Slominski AT. Inhibition of melanogenesis as a radiation sensitizer for melanoma therapy. Int J Cancer 2008; 123:1448-1456.
71. Slominski A, Zbytek B, Slominski R. Inhibitors of melanogenesis increase toxicity of cyclophosphamide and lymphocytes against melanoma cells. Int J Cancer 2009; 124:1470-1477.
72. Slominski A, Zmijewski MA, Pawelek J. L-tyrosine and L- dihydroxyphenylalanine as hormone-like regulators of melanocyte functions. Pigment Cell Melanoma Res 2012; 25:14-27.
73. Slominski AT, Zmijewski MA, Skobowiat C, Zbytek B, Slominski RM, Steketee JD. Sensing the environment: regulation of local and global homeostasis by the skin's neuroendocrine system. Adv Anat Embryol Cell Biol 2012; 212:1-115.
74. Colston K, Colston MJ, Feldman D. 1,25-dihydroxyvitamin D3 and malignant melanoma: the presence of receptors and inhibition of cell growth in culture. Endocrinology 1981; 108:1083-1086.
75. Evans SR, Houghton AM, Schumaker L, Brenner RV, Buras RR, Davoodi F, et al. Vitamin D receptor and growth inhibition by 1,25-dihydroxyvitamin D3 in human malignant melanoma cell lines. J Surg Res 1996; 61:127-133.
76. Slominski AT, Kim TK, Li W, Yid AK, Postlethwaite A, Tuckey RC. The role of CYP11A1 in the production of vitamin D metabolites and their role in the regulation of epidermal functions. J Steroid Biochem Mol Biol 2013 S0960-0760:00205-7. doi: 10.1016/j.jsbmb.2013.10.012. [Epub ahead of print].
77. Slominski A, Kim TK, Zmijewski MA, Janjetovic Z, Li W, Chen J, et al. Novel vitamin D photoproducts and their precursors in the skin. Dermatoendocrinol 2013; 5:7-19.
78. Köstner K, Denzer N, Müller CS, Klein R, Tilgen W, Reichrath J. The relevance of vitamin D receptor (VDR) gene polymorphisms for cancer: a review of the literature. Anticancer Res 2009; 29:3511-3536.
79. Randerson-Moor JA, Taylor JC, Elliott F, Chang YM, Beswick S, Kukalizch K, et al. Vitamin D receptor gene polymorphisms, serum 25-hydroxyvitamin D levels, and melanoma: UK case-control comparisons and a meta-analysis of published VDR data. Eur J Cancer 2009; 45:3271-3281.
80. Barroso E, Fernandez LP, Milne RL, Pita G, Sendagorta E, Floristan U, et al. Genetic analysis of the vitamin D receptor gene in two epithelial cancers: melanoma and breast cancer case-control studies. BMC Cancer 2008; 8:385.
81. Mocellin S, Nitti D. Vitamin D receptor polymorphisms and the risk of cutaneous melanoma: a systematic review and meta-analysis. Cancer 2008; 113:2398-2407.
82. Han J, Colditz GA, Hunter DJ. Polymorphisms in the MTHFR and VDR genes and skin cancer risk. Carcinogenesis 2007; 28:390-397.
83. d'Alésio A, Garabédian M, Sabatier JP, Guaydier- Souquières G, Marcelli C, Lemaçon A, et al. Two single-nucleotide polymorphisms in the human vitamin D receptor promoter change protein-DNA complex formation and are associated with height and vitamin D status in adolescent girls. Hum Mol Genet 2005; 14:3539-3548.
84. Uitterlinden AG, Fang Y, Van Meurs JB, Pols HA, Van Leeuwen JP. Genetics and biology of vitamin D receptor polymorphisms. Gene 2004; 338:143-156.
85. Mahmoudi T, Arkani M, Karimi K, Safaei A, Rostami F, Arbabi E, et al. The-4817GA (rs2238136) variant of the vitamin D receptor gene: a probable risk factor for colorectal cancer. Mol Biol Rep 2012; 39:5277-5282.
86. Hochberg Z, Templeton AR. Evolutionary perspective in skin color, vitamin D and its receptor. Hormones (Athens) 2010; 9:307-311.
87. Sturm RA, Duffy DL, Zhao ZZ, Leite FP, Stark MS, Hayward NK, et al. A single SNP in an evolutionary conserved region within intron 86 of the HERC2 gene determines human blue-brown eye color. Am J Hum Genet 2008; 82:424-431.
88. Fernandez LP, Milne RL, Pita G, Floristan U, Sendagorta E, Feito M, et al. Pigmentation-related genes and their implication in malignant melanoma susceptibility. Exp Dermatol 2009; 18:634-642.
89. Moore JH. The ubiquitous nature of epistasis in determining susceptibility to common human diseases. Hum Hered 2003; 56:73-82.
90. Carlborg O, Haley CS. Epistasis: too often neglected in complex trait studies? Nat Rev Genet 2004; 5:618-625.
91. Duffy DL, Box NF, Chen W, Palmer JS, Montgomery GW, James MR, et al. Interactive effects of MC1R and OCA2 on melanoma risk phenotypes. Hum Mol Genet 2004; 13:447-461.
92. Liu F, Wollstein A, Hysi PG, Ankra-Badu GA, Spector TD, Park D, et al. Digital quantification of human eye color highlights genetic association of three new loci. PLoS Genet 2010; 6:e1000934.